Neurocrine Biosciences, Inc.NBIXNASDAQ
LOADING
|||
Switch Symbol:
EPS Growth Under Pressure
Trending lower, above historical average, modest growth trend.
Left:
||||
Year-over-year earnings per share growth rate
Latest
93.58%
↑ 64% above average
Average (39q)
57.18%
Historical baseline
Range
High:1262.50%
Low:-704.11%
CAGR
+4.8%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 93.58% |
| Q2 2025 | 1262.50% |
| Q1 2025 | -92.23% |
| Q4 2024 | -19.53% |
| Q3 2024 | 100.00% |
| Q2 2024 | 48.84% |
| Q1 2024 | -71.33% |
| Q4 2023 | 76.47% |
| Q3 2023 | -13.27% |
| Q2 2023 | 224.05% |
| Q1 2023 | -185.87% |
| Q4 2022 | 27.78% |
| Q3 2022 | 500.00% |
| Q2 2022 | -220.00% |
| Q1 2022 | 295.06% |
| Q4 2021 | -132.04% |
| Q3 2021 | -46.67% |
| Q2 2021 | 32.35% |
| Q1 2021 | -90.86% |
| Q4 2020 | 700.00% |
| Q3 2020 | -172.09% |
| Q2 2020 | 115.00% |
| Q1 2020 | 8.11% |
| Q4 2019 | -37.29% |
| Q3 2019 | 5.36% |
| Q2 2019 | 150.00% |
| Q1 2019 | -660.00% |
| Q4 2018 | -64.29% |
| Q3 2018 | 953.66% |
| Q2 2018 | 86.04% |
| Q1 2018 | -704.11% |
| Q4 2017 | 159.85% |
| Q3 2017 | 80.88% |
| Q2 2017 | 24.44% |
| Q1 2017 | -76.47% |
| Q4 2016 | -18.60% |
| Q3 2016 | 6.52% |
| Q2 2016 | -109.09% |
| Q1 2016 | 35.29% |
| Q4 2015 | 15.00% |